[{"id":"52425dc1-74c8-49b8-8efe-2388d72e2562","acronym":"","url":"https://clinicaltrials.gov/study/NCT06172296","created_at":"2023-12-15T20:18:48.678Z","updated_at":"2025-02-25T14:04:06.256Z","phase":"Phase 3","brief_title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","source_id_and_acronym":"NCT06172296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TERT • MYCN","pipe":"","alterations":" ","tags":["ALK • TERT • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 04/19/2024","start_date":" 04/19/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-19"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"421063e1-092c-4069-8aae-f069c4e61471","acronym":"","url":"https://clinicaltrials.gov/study/NCT01174108","created_at":"2021-01-18T04:41:02.291Z","updated_at":"2025-02-25T15:25:06.019Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","source_id_and_acronym":"NCT01174108","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TERT • GATA2","pipe":" | ","alterations":" TERT mutation • GATA2 mutation","tags":["TERT • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • GATA2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/10/2010","start_date":" 12/10/2010","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-11"},{"id":"fb005881-4dad-4aee-8405-d3b9ee7b7d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463848","created_at":"2022-07-19T15:55:14.520Z","updated_at":"2025-02-25T16:17:57.365Z","phase":"Phase 2","brief_title":"Surgical Pembro +/- Olaparib W TMZ for RGBM","source_id_and_acronym":"NCT05463848","lead_sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • IDH wild-type","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/21/2022","start_date":" 10/21/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-06"},{"id":"1f0415b7-1012-4eac-85aa-31006ac84270","acronym":"","url":"https://clinicaltrials.gov/study/NCT06718153","created_at":"2025-02-26T10:22:38.573Z","updated_at":"2025-02-26T10:22:38.573Z","phase":"","brief_title":"Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation","source_id_and_acronym":"NCT06718153","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" TP53 • TERT • CTNNB1","pipe":"","alterations":" ","tags":["TP53 • TERT • CTNNB1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/23/2024","start_date":" 10/23/2024","primary_txt":" Primary completion: 05/13/2025","primary_completion_date":" 05/13/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-05"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"aebfc79a-06bb-47ab-a81d-a5954af2fab2","acronym":"PATHWAyS","url":"https://clinicaltrials.gov/study/NCT05900908","created_at":"2023-06-13T17:07:56.192Z","updated_at":"2024-07-02T16:35:19.451Z","phase":"Phase 4","brief_title":"Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy","source_id_and_acronym":"NCT05900908 - PATHWAyS","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-02-14"},{"id":"9ac5a259-2a1d-4705-a42a-0a8634a71850","acronym":"","url":"https://clinicaltrials.gov/study/NCT06236464","created_at":"2024-02-01T18:21:37.212Z","updated_at":"2024-07-02T16:35:21.338Z","phase":"","brief_title":"Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas","source_id_and_acronym":"NCT06236464","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 11/19/2025","primary_completion_date":" 11/19/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-01"},{"id":"7cf86a02-5513-448e-bed8-5d1eed5bad20","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162420","created_at":"2021-01-18T10:04:00.879Z","updated_at":"2024-07-02T16:35:22.078Z","phase":"","brief_title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","source_id_and_acronym":"NCT02162420","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" TERT • DKC1","pipe":"","alterations":" ","tags":["TERT • DKC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/10/2015","start_date":" 01/10/2015","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-01-26"},{"id":"8943f47c-7aa3-4bea-83e0-413753bdafd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102525","created_at":"2023-10-26T15:14:16.345Z","updated_at":"2024-07-02T16:35:31.481Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","source_id_and_acronym":"NCT06102525","lead_sponsor":"Rznomics, Inc.","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RZ-001 • Valcyte (valganciclovir)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2023-10-26"},{"id":"ee79acb6-a7a2-420e-8c81-cb89ac6094da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03058588","created_at":"2021-01-18T15:03:55.450Z","updated_at":"2024-07-02T16:35:42.278Z","phase":"","brief_title":"Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes","source_id_and_acronym":"NCT03058588","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" TERT • RUNX1 • ETV6 • GATA2 • ANKRD26","pipe":" | ","alterations":" ETV6 mutation","tags":["TERT • RUNX1 • ETV6 • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETV6 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-07-21"},{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"},{"id":"6f24da17-d18e-4f79-befe-3764e25c2b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05271240","created_at":"2022-03-08T16:52:43.604Z","updated_at":"2024-07-02T16:35:47.014Z","phase":"Phase 3","brief_title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","source_id_and_acronym":"NCT05271240","lead_sponsor":"Northwell Health","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 432","initiation":"Initiation: 04/27/2022","start_date":" 04/27/2022","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-05-29"},{"id":"9281feb2-76be-43ef-aaa8-b34124c78001","acronym":"","url":"https://clinicaltrials.gov/study/NCT04924127","created_at":"2021-06-11T18:56:22.686Z","updated_at":"2024-07-02T16:35:50.094Z","phase":"","brief_title":"Molecular Pathology Research Project of Glioma","source_id_and_acronym":"NCT04924127","lead_sponsor":"Jinsong Wu","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Completed","enrollment":" Enrollment 976","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 06/06/2021","primary_completion_date":" 06/06/2021","study_txt":" Completion: 12/20/2021","study_completion_date":" 12/20/2021","last_update_posted":"2023-04-19"},{"id":"aab294a4-1ca3-4b85-ab41-94be4ce929be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04904419","created_at":"2021-05-27T12:53:02.570Z","updated_at":"2024-07-02T16:35:50.199Z","phase":"","brief_title":"Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection","source_id_and_acronym":"NCT04904419","lead_sponsor":"Jinsong Wu","biomarkers":" BRAF • TERT","pipe":" | ","alterations":" BRAF V600E • TERT mutation","tags":["BRAF • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • TERT mutation"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/31/2022","primary_completion_date":" 01/31/2022","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2023-04-18"},{"id":"dfc3a399-9a0f-4709-8f4e-69c5187b4188","acronym":"CRUKD/17/003","url":"https://clinicaltrials.gov/study/NCT03371485","created_at":"2023-03-22T18:03:32.842Z","updated_at":"2024-07-02T16:35:52.683Z","phase":"Phase 1","brief_title":"AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03371485 - CRUKD/17/003","lead_sponsor":"Cancer Research UK","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VAC2"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 08/08/2022","primary_completion_date":" 08/08/2022","study_txt":" Completion: 08/08/2022","study_completion_date":" 08/08/2022","last_update_posted":"2023-03-22"},{"id":"fa2b0640-f5ce-4b88-b935-f975161dbe80","acronym":"TEMPEST","url":"https://clinicaltrials.gov/study/NCT05752669","created_at":"2023-03-03T15:01:27.972Z","updated_at":"2024-07-02T16:35:54.080Z","phase":"","brief_title":"Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.","source_id_and_acronym":"NCT05752669 - TEMPEST","lead_sponsor":"Istituto Auxologico Italiano","biomarkers":" BRAF • TERT","pipe":"","alterations":" ","tags":["BRAF • TERT"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2023-03-06"},{"id":"aff38d03-8427-4efd-9ff1-ec4481379fbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595473","created_at":"2022-10-27T15:58:19.813Z","updated_at":"2024-07-02T16:36:01.714Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05595473","lead_sponsor":"Rznomics, Inc.","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RZ-001 • Valcyte (valganciclovir)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2022-10-27"},{"id":"93bff278-c608-420e-b03d-f427d89bfe6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00604201","created_at":"2021-01-18T02:14:32.083Z","updated_at":"2024-07-02T16:36:18.819Z","phase":"Phase 2","brief_title":"Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome","source_id_and_acronym":"NCT00604201","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TERT • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" TERT mutation","tags":["TERT • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 05/21/2008","start_date":" 05/21/2008","primary_txt":" Primary completion: 10/25/2016","primary_completion_date":" 10/25/2016","study_txt":" Completion: 09/14/2021","study_completion_date":" 09/14/2021","last_update_posted":"2022-01-05"},{"id":"8a7bbd71-8642-4694-a50d-cc6f1326a302","acronym":"","url":"https://clinicaltrials.gov/study/NCT01404949","created_at":"2021-01-18T05:46:30.343Z","updated_at":"2024-07-02T16:36:20.058Z","phase":"Phase 2","brief_title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","source_id_and_acronym":"NCT01404949","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TERT • PML","pipe":"","alterations":" ","tags":["TERT • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-11-30"},{"id":"cc53a890-89ed-4959-a512-acb62dcd9222","acronym":"HELP-2020","url":"https://clinicaltrials.gov/study/NCT04506398","created_at":"2021-06-24T18:52:50.426Z","updated_at":"2024-07-02T16:36:28.684Z","phase":"","brief_title":"Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence","source_id_and_acronym":"NCT04506398 - HELP-2020","lead_sponsor":"RenJi Hospital","biomarkers":" TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3","pipe":" | ","alterations":" CTNNB1 mutation • TERT mutation • TERT promoter mutation","tags":["TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation • TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-06-24"},{"id":"be90799f-136d-496d-adb9-c7981cf760f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792437","created_at":"2021-03-11T13:52:40.593Z","updated_at":"2024-07-02T16:36:32.874Z","phase":"","brief_title":"Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data","source_id_and_acronym":"NCT04792437","lead_sponsor":"Yu Yao, MD","biomarkers":" PD-L1 • TMB • CD8 • TERT • PD-1 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD8 expression • TERT mutation","tags":["PD-L1 • TMB • CD8 • TERT • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression • TERT mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2021-03-24"}]